Imetelstat
Imetelstat (development code GRN163L) is an experimental anticancer drug.[1] It is the first telomerase inhibitor to enter clinical trials.[2] It is currently in Phase 2/3 trials for various cancer types.[2]
Clinical data | |
---|---|
Other names | GRN163L |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C148H210N68O53P13S13 |
Molar mass | 4610 |
3D model (JSmol) | |
| |
|
Chemically, imetelstat is a synthetic conjugate consisting of three parts: GRN163, a thiophosphoramide oligonucleotide, and a palmitoyl lipid group.[2] GRN163 is the pharmacological component with telomerase inhibition.[3]
References
- Katrina M. Burchett, Ying Yan, and Michel M. Ouellette (2014). "Telomerase Inhibitor Imetelstat (GRN163L) Limits the Lifespan of Human Pancreatic Cancer Cells". doi:10.1371/journal.pone.0085155. Cite journal requires
|journal=
(help)CS1 maint: multiple names: authors list (link) - Nicola Relitti, Akella P Saraswati, Stefano Federico, Tuhina Khan, Margherita Brindisi, Daniela Zisterer, Simone Brogi, Sandra Gemma, Stefania Butini, Giuseppe Campiani (2020). "Telomerase-based Cancer Therapeutics: A Review on their Clinical Trials". Current Topics in Medicinal Chemistry. doi:10.2174/1568026620666200102104930. PMID 31894749.CS1 maint: multiple names: authors list (link)
- Meta W. Djojosubroto, Allison C. Chin, Ning Go, Sonja Schaetzlein, Michael P. Manns, Sergei Gryaznov, Calvin B. Harley, K. Lenhard Rudolph (2005). "Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma". Hepatology. doi:10.1002/hep.20822.CS1 maint: multiple names: authors list (link)
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.